Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of toripalimab plus nab-paclitaxel and cisplatin/carboplatin as induction therapy for locally advanced head and neck squamous cell carcinoma
ChiCTR2600132403Phase 2Not yet recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Sep 2026
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab, paclitaxel, cisplatin and carboplatin in head and neck squamous cell carcinoma (HNSCC), sponsored by Peking Union Medical College Hospital. Primary endpoint: Progression-free survival. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
toripalimabpaclitaxelcisplatincarboplatin
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on ChiCTR2600132403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600132403.